NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam Pharma" or the "Company"), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. ET.
荷兰纳尔登和迈阿密，9月1日2023年20日(环球网)--临床阶段生物制药公司新阿姆斯特丹制药公司(纳斯达克代码：NAMS或“新阿姆斯特丹制药公司”或“公司”)今天宣布，纽阿姆斯特丹制药公司首席执行官迈克尔·戴维森将参加2023年9月27日(星期三)坎托·菲茨杰拉德全球医疗会议的炉边聊天。该公司是一家临床阶段的生物制药公司，为低密度脂蛋白胆固醇(“LDL-C”)残留升高的心血管疾病高危患者开发口服非他汀类药物2023年下午1：50Et.
A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company's website.
炉边谈话的网络直播将通过新阿姆斯特丹制药公司网站的投资者关系部分进行，网址为ir.newamsterDampharma.com。在网络直播之后，将在公司网站上进行存档重播。
About NewAmsterdam
关于新阿姆斯特丹
Based in the Netherlands, NewAmsterdam (Nasdaq: NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently adequate or well tolerated. We seek to fill a significant unmet need for a safe, cost-effective and convenient LDL-lowering therapy as an adjunct to statins, a class of lipid-lowering medications that are the current standard of care for high-risk CVD patients with high cholesterol. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients.
总部设在荷兰的新阿姆斯特丹公司(纳斯达克代码：NAMS)是一家临床阶段的生物制药公司，其使命是改善患有代谢性疾病的人群的患者护理，这些人群目前批准的治疗方法不够充分或耐受性不佳。我们寻求满足一个重要的未得到满足的需求，即作为他汀类药物的补充，安全、成本效益高和方便的降低低密度脂蛋白疗法，他汀类药物是一类降脂药物，目前是高风险心血管疾病高胆固醇患者的护理标准。新阿姆斯特丹正在研究ObicetRapib，一种口服、低剂量、每天一次的CETP抑制剂，作为高风险心血管疾病患者最大耐受性他汀类药物的首选降低低密度脂蛋白的辅助疗法。
Company Contact
公司联系人
Matthew Philippe
P: 917-882-7512
matthew.philippe@newamsterdampharma.com
马修·菲利普
电话：917-882-7512
邮箱：matthew.philippe@newamsterDampharma.com
Media Contact
媒体联系人
Spectrum Science on behalf of NewAmsterdam
Jenn Gordon
P: 1-202-957-7795
jgordon@spectrumscience.com
代表新阿姆斯特丹的光谱科学
珍妮·戈登
电话：1-202-957-7795
邮箱：jgordon@spectrumcerence.com
Investor Contact
投资者联系方式
Stern Investor Relations on behalf of NewAmsterdam
Hannah Deresiewicz
P: 1 212-362-1200
hannah.deresiewicz@sternir.com
代表新阿姆斯特丹的斯特恩投资者关系
汉娜·德雷谢维奇
电话：1212-362-1200
邮箱：hannah.deresiewicz@sternir.com